Loading...
StocksRunner logo
 
 
Annexon
2.81
-2.60%
 
ANNX Annexon
Last Price
Change
2.81
 
-2.60%
 
 
 

 
Sentiment
 
 

5.47

4.07

7.06

4

 
 
1m
3m
6m
1y
 

Summary

  Login to display Annexon (ANNX) recommendation from the last 90 days from financial news and social media.
 

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Trading below its fair value

 
 

Risk Level

 
StocksRunner
 

Annexon (ANNX) has High Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

2.00
 

StocksRunner

 Reported a weak earnings

 
 

Rating

×
 

Rating

3.40
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

2.00
 

StocksRunner

 Price value has negative momentum

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

5.00
 

StocksRunner

 Trading below its fair value

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
53%
60%
0%
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is bullish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
53%
47%
Positive
Negative
9 out of 17
events present
8 out of 17
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Weak Earnings
1 Week Ago
2.74
-3.86%
 
Downgrade
2 Weeks Ago
2.85
+35.71%
 
Buy Rating
2 Weeks Ago
2.10
-59.48%
 
Buy Rating
2 Month Ago
5.45
+3.81%
 
Buy Rating
2 Month Ago
5.22
+0.58%
 
Top Headlines

annexon (annx) stock down more than 50% last week: heres why. annexon&rsquo.s annx stock declined 51.7% last week after it reported mixed results from a phase ii study on its lead pipeline cand

Tue May 30, 2023

Earnings
Momentum

: annexon downgraded to neutral from buy at bofa securities. this is a real-time headline. these are breaking news delivered the minute it happens delivered ticker-tape style. visit www.marketwatch.com or the e page for more information about this breakin

Fri May 26, 2023

Rating

annexon cut at bofa on mid-stage eye disease data.

Fri May 26, 2023

Rating

bofa securities downgrades annexon to neutral with a price target of $3.00.

Fri May 26, 2023

Rating

btig maintains annexon (annx) buy recommendation. fintel reports that on may 25 2023 btig maintained coverage of annexon (nasdaq:annx) with a buy recommendation.

Thu May 25, 2023

Rating

needham reiterates annexon (annx) buy recommendation. fintel reports that on may 25 2023 needham reiterated coverage of annexon (nasdaq:annx) with a buy recommendation.

Thu May 25, 2023

Rating

hc wainwright & co. reiterates annexon (annx) buy recommendation. fintel reports that on may 25 2023 hc wainwright &. co. reiterated coverage of annexon (nasdaq:annx) with a buy recommendation.

Thu May 25, 2023

Rating

why shares of annexon are plummeting thursday. what happened shares of annexon (nasdaq: annx) were down more than 57% on thursday after the company reported mixed results for an eye disease therapy late wednesday. the clinical-stage healthcare

Thu May 25, 2023

Earnings

why annexon (annx) stock is getting hammered. ) shares are trading lower by some 57.16% to $2.96 thursday morning. the company announced topline results from its archer phase 2 trial of anx007 inpatients with

Thu May 25, 2023

Activity
Momentum

annexon off 58% after setback for eye disease candidate. jpmorgan downgrades.

Thu May 25, 2023

Rating

hc wainwright & co. reiterates annexon (annx) buy recommendation. fintel reports that on may 9 2023 hc wainwright &. co. reiterated coverage of annexon (nasdaq:annx) with a buy recommendation.

Tue May 9, 2023

Rating

needham reiterates annexon (annx) buy recommendation. fintel reports that on may 9 2023 needham reiterated coverage of annexon (nasdaq:annx) with a buy recommendation.

Tue May 9, 2023

Rating

needham reiterates annexon (annx) buy recommendation. fintel reports that on april 19 2023 needham reiterated coverage of annexon (nasdaq:annx) with a buy recommendation.

Thu Apr 20, 2023

Rating

annexon: attractive below-radar undervalued stock.

Tue Apr 18, 2023

Potential

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily ANNX alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

ANNX Annexon

Last Price
2.81
Change
-2.60%
 

Summary

  Login to display Annexon (ANNX) recommendation from the last 90 days from financial news and social media.

 
 
5.47
4.07
7.06
4
 
 
1m
3m
6m
1y
 
Sentiment

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Trading below its fair value

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
60%
0%
100%
On Track
On Track
On Track
 
53%
47%
Positive
Negative
9 out of 17
events present
8 out of 17
events present
 

Street Opinion

Street view is bullish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

2.00
 

StocksRunner

 Reported a weak earnings

 
 

Rating

×
 

Rating

3.40
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

2.00
 

StocksRunner

 Price value has negative momentum

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

5.00
 

StocksRunner

 Trading below its fair value

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

Annexon (ANNX) has High Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Weak Earnings
1 Week Ago
2.74
-3.86%
 
Downgrade
2 Weeks Ago
2.85
+35.71%
 
Buy Rating
2 Weeks Ago
2.10
-59.48%
 
Buy Rating
2 Month Ago
5.45
+3.81%
 
Buy Rating
2 Month Ago
5.22
+0.58%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily ANNX Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines